Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluocinolone acetonide + urea is a topical combination product containing a synthetic corticosteroid (fluocinolone acetonide) and a keratolytic/humectant agent (urea), used primarily for the treatment of corticosteroid-responsive dermatoses, such as eczema, dermatitis, psoriasis, and other inflammatory skin disorders. Fluocinolone acetonide acts as an anti-inflammatory agent by binding to the glucocorticoid receptor, altering gene transcription, reducing the production of pro-inflammatory mediators (such as prostaglandins and leukotrienes) via phospholipase A2 inhibition, and inducing annexin proteins. Urea improves skin hydration by breaking down keratin, which helps enhance drug penetration and reduces scaling. The combination targets both inflammation and hyperkeratosis commonly seen in chronic dermatoses[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluocinolone acetonide + urea.